BioAtla, Inc. (NASDAQ:BCAB) was down 4.7% on Tuesday . The company traded as low as $48.25 and last traded at $48.36. Approximately 1,897 shares changed hands during trading, a decline of 99% from the average daily volume of 290,481 shares. The stock had previously closed at $50.77.
BCAB has been the topic of several recent analyst reports. JPMorgan Chase & Co. assumed coverage on shares of BioAtla in a research note on Monday, January 11th. They set an “overweight” rating and a $45.00 price objective for the company. Credit Suisse Group assumed coverage on shares of BioAtla in a report on Monday, January 11th. They issued an “outperform” rating and a $49.00 price objective on the stock. BTIG Research raised their target price on shares of BioAtla from $47.00 to $87.00 and gave the stock a “buy” rating in a research note on Thursday, April 1st. Finally, Jefferies Financial Group started coverage on BioAtla in a research note on Monday, January 11th. They issued a “buy” rating and a $51.00 price objective for the company.
The business’s 50-day moving average price is $56.82.
A number of institutional investors and hedge funds have recently bought and sold shares of BCAB. SG Americas Securities LLC acquired a new stake in BioAtla in the 4th quarter valued at about $401,000. BlackRock Inc. acquired a new stake in BioAtla in the 4th quarter valued at approximately $4,993,000. Monashee Investment Management LLC purchased a new stake in shares of BioAtla in the 4th quarter valued at $680,000. Laurion Capital Management LP purchased a new position in shares of BioAtla in the fourth quarter valued at approximately $680,000. Finally, Caas Capital Management LP acquired a new stake in shares of BioAtla in the fourth quarter valued at $2,381,000.
BioAtla Company Profile (NASDAQ:BCAB)
BioAtla, Inc, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.